Brussels, Belgium, August 31, 2022 – Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable production of advanced therapies, is announcing the appointment of Florence Vicaire as Chief Commercial Officer (CCO). In this newly created role, Ms. Vicaire will be responsible for the commercialization and continued expansion of the company’s enabling portfolio of biomanufacturing technologies and services, which include the scale-X™ and NevoLine™ platforms.
“This appointment reflects our commitment to strategic development and expansion within the gene therapy market. We are investing in a sustainable and scalable infrastructure driven by leaders that we are confident in,” said CEO Mathias Garny. “Florence joins this team with many years of global experience in sales and leadership in Life Sciences that will benefit our employees and customers, as Univercells Technologies enters the next stage of growth. Her track record of strong commercial leadership will be crucial as we step forward and expand the existing product line, while investigating new markets and modalities to develop and launch innovative products and services.”
“When I connected with the talented and motivated Univercells Technologies team, I was impressed by their high level of standards. The team is passionate about finding meaningful game-changing solutions to critical biomanufacturing challenges in the rapidly growing market for next-generation therapies,” said Florence Vicaire, incoming CCO at Univercells Technologies. “As I begin this appointment, I plan to build a deeper commercial foundation for the company. Bringing the concepts of integration and intensification to bioprocessing will offer solutions that contribute to the development of life-saving therapies.”
Florence Vicaire brings extensive experience in developing and structuring businesses in life sciences and bioprocess sectors across Europe, Asia, and the US, most recently as Gene Therapy Global Business Leader at Cytiva. Previously, she played a key role in successfully commercializing the iCELLis® bioreactor portfolio at ATMI Life Sciences, as well as founding and serving as CEO for a point of care diagnostic biotech start-up. Florence holds an engineer degree in Biotechnology from the UTC Compiègne and an MBA in Marketing and Business Management from the ESSEC business school.
About Univercells Technologies
Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective advanced therapies production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.
Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 following its carve-out from Univercells with the support of the Univercells Group and Gamma Biosciences.
LinkedIn: Univercells Technologies